Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer
Purpose: Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving CSC-specific markers and related mechanisms in SCLC remain limited. This study explored the role of the voltage-dependent calcium channel α2δ1 s...
Saved in:
Published in | Clinical cancer research Vol. 24; no. 9; pp. 2148 - 2158 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Association for Cancer Research Inc
01.05.2018
|
Subjects | |
Online Access | Get full text |
ISSN | 1078-0432 1557-3265 1557-3265 |
DOI | 10.1158/1078-0432.CCR-17-1932 |
Cover
Loading…
Abstract | Purpose: Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving CSC-specific markers and related mechanisms in SCLC remain limited. This study explored the role of the voltage-dependent calcium channel α2δ1 subunit as a CSC marker in chemoresistance of SCLC, and explored the potential mechanisms of α2δ1-mediated chemoresistance and strategies of overcoming the resistance.
Experimental Design: α2δ1-positive cells were identified and isolated from SCLC cell lines and patient-derived xenograft (PDX) models, and CSC-like properties were subsequently verified. Transcriptome sequencing and Western blotting were carried out to identify pathways involved in α2δ1-mediated chemoresistance in SCLC. In addition, possible interventions to overcome α2δ1-mediated chemoresistance were examined.
Results: Different proportions of α2δ1+ cells were identified in SCLC cell lines and PDX models. α2δ1+ cells exhibited CSC-like properties (self-renewal, tumorigenic, differentiation potential, and high expression of genes related to CSCs and drug resistance). Chemotherapy induced the enrichment of α2δ1+ cells instead of CD133+ cells in PDXs, and an increased proportion of α2δ1+ cells corresponded to increased chemoresistance. Activation and overexpression of ERK in the α2δ1-positive H1048 cell line was identified at the protein level. mAb 1B50-1 was observed to improve the efficacy of chemotherapy and delay relapse as maintenance therapy in PDX models.
Conclusions: SCLC cells expressing α2δ1 demonstrated CSC-like properties, and may contribute to chemoresistance. ERK may play a key role in α2δ1-mediated chemoresistance. mAb 1B50-1 may serve as a potential anti-SCLC drug. Clin Cancer Res; 24(9); 2148–58. ©2018 AACR. |
---|---|
AbstractList | Purpose: Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving CSC-specific markers and related mechanisms in SCLC remain limited. This study explored the role of the voltage-dependent calcium channel α2δ1 subunit as a CSC marker in chemoresistance of SCLC, and explored the potential mechanisms of α2δ1-mediated chemoresistance and strategies of overcoming the resistance.
Experimental Design: α2δ1-positive cells were identified and isolated from SCLC cell lines and patient-derived xenograft (PDX) models, and CSC-like properties were subsequently verified. Transcriptome sequencing and Western blotting were carried out to identify pathways involved in α2δ1-mediated chemoresistance in SCLC. In addition, possible interventions to overcome α2δ1-mediated chemoresistance were examined.
Results: Different proportions of α2δ1+ cells were identified in SCLC cell lines and PDX models. α2δ1+ cells exhibited CSC-like properties (self-renewal, tumorigenic, differentiation potential, and high expression of genes related to CSCs and drug resistance). Chemotherapy induced the enrichment of α2δ1+ cells instead of CD133+ cells in PDXs, and an increased proportion of α2δ1+ cells corresponded to increased chemoresistance. Activation and overexpression of ERK in the α2δ1-positive H1048 cell line was identified at the protein level. mAb 1B50-1 was observed to improve the efficacy of chemotherapy and delay relapse as maintenance therapy in PDX models.
Conclusions: SCLC cells expressing α2δ1 demonstrated CSC-like properties, and may contribute to chemoresistance. ERK may play a key role in α2δ1-mediated chemoresistance. mAb 1B50-1 may serve as a potential anti-SCLC drug. Clin Cancer Res; 24(9); 2148–58. ©2018 AACR. Purpose: Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving CSC-specific markers and related mechanisms in SCLC remain limited. This study explored the role of the voltage-dependent calcium channel α2δ1 subunit as a CSC marker in chemoresistance of SCLC, and explored the potential mechanisms of α2δ1-mediated chemoresistance and strategies of overcoming the resistance.Experimental Design: α2δ1-positive cells were identified and isolated from SCLC cell lines and patient-derived xenograft (PDX) models, and CSC-like properties were subsequently verified. Transcriptome sequencing and Western blotting were carried out to identify pathways involved in α2δ1-mediated chemoresistance in SCLC. In addition, possible interventions to overcome α2δ1-mediated chemoresistance were examined.Results: Different proportions of α2δ1+ cells were identified in SCLC cell lines and PDX models. α2δ1+ cells exhibited CSC-like properties (self-renewal, tumorigenic, differentiation potential, and high expression of genes related to CSCs and drug resistance). Chemotherapy induced the enrichment of α2δ1+ cells instead of CD133+ cells in PDXs, and an increased proportion of α2δ1+ cells corresponded to increased chemoresistance. Activation and overexpression of ERK in the α2δ1-positive H1048 cell line was identified at the protein level. mAb 1B50-1 was observed to improve the efficacy of chemotherapy and delay relapse as maintenance therapy in PDX models.Conclusions: SCLC cells expressing α2δ1 demonstrated CSC-like properties, and may contribute to chemoresistance. ERK may play a key role in α2δ1-mediated chemoresistance. mAb 1B50-1 may serve as a potential anti-SCLC drug. Clin Cancer Res; 24(9); 2148-58. ©2018 AACR.Purpose: Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving CSC-specific markers and related mechanisms in SCLC remain limited. This study explored the role of the voltage-dependent calcium channel α2δ1 subunit as a CSC marker in chemoresistance of SCLC, and explored the potential mechanisms of α2δ1-mediated chemoresistance and strategies of overcoming the resistance.Experimental Design: α2δ1-positive cells were identified and isolated from SCLC cell lines and patient-derived xenograft (PDX) models, and CSC-like properties were subsequently verified. Transcriptome sequencing and Western blotting were carried out to identify pathways involved in α2δ1-mediated chemoresistance in SCLC. In addition, possible interventions to overcome α2δ1-mediated chemoresistance were examined.Results: Different proportions of α2δ1+ cells were identified in SCLC cell lines and PDX models. α2δ1+ cells exhibited CSC-like properties (self-renewal, tumorigenic, differentiation potential, and high expression of genes related to CSCs and drug resistance). Chemotherapy induced the enrichment of α2δ1+ cells instead of CD133+ cells in PDXs, and an increased proportion of α2δ1+ cells corresponded to increased chemoresistance. Activation and overexpression of ERK in the α2δ1-positive H1048 cell line was identified at the protein level. mAb 1B50-1 was observed to improve the efficacy of chemotherapy and delay relapse as maintenance therapy in PDX models.Conclusions: SCLC cells expressing α2δ1 demonstrated CSC-like properties, and may contribute to chemoresistance. ERK may play a key role in α2δ1-mediated chemoresistance. mAb 1B50-1 may serve as a potential anti-SCLC drug. Clin Cancer Res; 24(9); 2148-58. ©2018 AACR. Purpose: Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving CSC-specific markers and related mechanisms in SCLC remain limited. This study explored the role of the voltage-dependent calcium channel α2δ1 subunit as a CSC marker in chemoresistance of SCLC, and explored the potential mechanisms of α2δ1-mediated chemoresistance and strategies of overcoming the resistance.Experimental Design: α2δ1-positive cells were identified and isolated from SCLC cell lines and patient-derived xenograft (PDX) models, and CSC-like properties were subsequently verified. Transcriptome sequencing and Western blotting were carried out to identify pathways involved in α2δ1-mediated chemoresistance in SCLC. In addition, possible interventions to overcome α2δ1-mediated chemoresistance were examined.Results: Different proportions of α2δ1+ cells were identified in SCLC cell lines and PDX models. α2δ1+ cells exhibited CSC-like properties (self-renewal, tumorigenic, differentiation potential, and high expression of genes related to CSCs and drug resistance). Chemotherapy induced the enrichment of α2δ1+ cells instead of CD133+ cells in PDXs, and an increased proportion of α2δ1+ cells corresponded to increased chemoresistance. Activation and overexpression of ERK in the α2δ1-positive H1048 cell line was identified at the protein level. mAb 1B50-1 was observed to improve the efficacy of chemotherapy and delay relapse as maintenance therapy in PDX models.Conclusions: SCLC cells expressing α2δ1 demonstrated CSC-like properties, and may contribute to chemoresistance. ERK may play a key role in α2δ1-mediated chemoresistance. mAb 1B50-1 may serve as a potential anti-SCLC drug. Clin Cancer Res; 24(9); 2148–58. ©2018 AACR. Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving CSC-specific markers and related mechanisms in SCLC remain limited. This study explored the role of the voltage-dependent calcium channel α2δ1 subunit as a CSC marker in chemoresistance of SCLC, and explored the potential mechanisms of α2δ1-mediated chemoresistance and strategies of overcoming the resistance. α2δ1-positive cells were identified and isolated from SCLC cell lines and patient-derived xenograft (PDX) models, and CSC-like properties were subsequently verified. Transcriptome sequencing and Western blotting were carried out to identify pathways involved in α2δ1-mediated chemoresistance in SCLC. In addition, possible interventions to overcome α2δ1-mediated chemoresistance were examined. Different proportions of α2δ1 cells were identified in SCLC cell lines and PDX models. α2δ1 cells exhibited CSC-like properties (self-renewal, tumorigenic, differentiation potential, and high expression of genes related to CSCs and drug resistance). Chemotherapy induced the enrichment of α2δ1 cells instead of CD133 cells in PDXs, and an increased proportion of α2δ1 cells corresponded to increased chemoresistance. Activation and overexpression of ERK in the α2δ1-positive H1048 cell line was identified at the protein level. mAb 1B50-1 was observed to improve the efficacy of chemotherapy and delay relapse as maintenance therapy in PDX models. SCLC cells expressing α2δ1 demonstrated CSC-like properties, and may contribute to chemoresistance. ERK may play a key role in α2δ1-mediated chemoresistance. mAb 1B50-1 may serve as a potential anti-SCLC drug. . |
Author | Zhao, Wei Bai, Hua Chen, Hanxiao Yu, Jiangyong Duan, Jianchun Wang, Di Wang, Jie An, Tongtong Wang, Shuhang Wu, Meina Zhao, Jun Wang, Zhijie Tian, Yanhua |
Author_xml | – sequence: 1 givenname: Jiangyong surname: Yu fullname: Yu, Jiangyong – sequence: 2 givenname: Shuhang surname: Wang fullname: Wang, Shuhang – sequence: 3 givenname: Wei surname: Zhao fullname: Zhao, Wei – sequence: 4 givenname: Jianchun surname: Duan fullname: Duan, Jianchun – sequence: 5 givenname: Zhijie surname: Wang fullname: Wang, Zhijie – sequence: 6 givenname: Hanxiao surname: Chen fullname: Chen, Hanxiao – sequence: 7 givenname: Yanhua surname: Tian fullname: Tian, Yanhua – sequence: 8 givenname: Di surname: Wang fullname: Wang, Di – sequence: 9 givenname: Jun surname: Zhao fullname: Zhao, Jun – sequence: 10 givenname: Tongtong surname: An fullname: An, Tongtong – sequence: 11 givenname: Hua surname: Bai fullname: Bai, Hua – sequence: 12 givenname: Meina surname: Wu fullname: Wu, Meina – sequence: 13 givenname: Jie surname: Wang fullname: Wang, Jie |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29437792$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkc1u1TAQhS1URH_gEUCW2LBxsZ24TsQKhfIj3QqpF9hajjNpXRw72I5EX4Z3QOI5-kw47S2LbljZsr8zZ2bOIdrzwQNCzxk9Zkw0rxmVDaF1xY-77pwwSVhb8UfogAkhScVPxF653zP76DClK0pZzWj9BO3ztq6kbPkB-nUG5lJ7m7I1-PTn7ELU2QaPw4g77Q1EvM0w4Q6cw2c6fi8P34LL-gLIO5jBD-BzIZ2xS6FKKQ8O3_zmN38Y3i794m0mEwxWZxjKP0whX0LU8zU-h1RsVw9sPd5O2jlya7NZ_MXO_Cl6PGqX4NnuPEJf359-6T6SzecPn7q3G2J43XAiOGP1yKq6EQOTJ7LvjRAj7UVlysC1lMIM0rS6hbEBYEYOvO1lPw6t0aZpaHWEXt3VnWP4sUDKarLJlGa0h7AkxSnlnDayYgV9-QC9Ckv0pbtClcWv_rJQL3bU0pfx1RztpOO1ut98AcQdYGJIKcL4D2FUrQmrNT21pqdKwopJtSZcdG8e6IzNt5HlqK37j_ovhwCtTg |
CitedBy_id | crossref_primary_10_1007_s12035_023_03560_z crossref_primary_10_1016_j_ceca_2022_102673 crossref_primary_10_3389_fonc_2022_899987 crossref_primary_10_1038_s41419_021_03522_0 crossref_primary_10_1016_j_bbcan_2021_188629 crossref_primary_10_1186_s12885_023_11761_x crossref_primary_10_3390_cells11081332 crossref_primary_10_2174_1566524019666190226104909 crossref_primary_10_1007_s11864_024_01245_w crossref_primary_10_3390_polym13081254 crossref_primary_10_1016_j_ceca_2019_05_006 crossref_primary_10_1016_j_clon_2020_05_017 crossref_primary_10_3390_cancers13102314 crossref_primary_10_1016_j_ceca_2019_05_001 crossref_primary_10_1097_JCMA_0000000000000186 crossref_primary_10_3389_fimmu_2020_01280 crossref_primary_10_3390_ijms231810687 crossref_primary_10_3390_cancers12030684 crossref_primary_10_18203_issn_2454_2156_IntJSciRep20240715 crossref_primary_10_3390_cancers11030376 crossref_primary_10_1245_s10434_021_09645_0 crossref_primary_10_3390_cells12101376 crossref_primary_10_1097_CAD_0000000000000865 crossref_primary_10_1186_s43066_020_00053_9 crossref_primary_10_1002_cac2_12351 crossref_primary_10_1245_s10434_022_11752_5 crossref_primary_10_1515_med_2021_0356 crossref_primary_10_1002_kjm2_12930 crossref_primary_10_3390_ijms20102505 crossref_primary_10_1016_j_bcp_2019_08_005 crossref_primary_10_1016_j_biopha_2023_115167 crossref_primary_10_1245_s10434_021_09647_y crossref_primary_10_1002_cam4_4950 crossref_primary_10_1016_j_ygeno_2020_12_045 crossref_primary_10_1155_2022_3242482 crossref_primary_10_3389_fonc_2022_945896 crossref_primary_10_3233_CBM_181947 crossref_primary_10_1093_schbul_sbz114 crossref_primary_10_1002_2211_5463_13230 crossref_primary_10_1038_s41392_022_01150_4 crossref_primary_10_1016_j_ceca_2019_04_005 crossref_primary_10_1371_journal_pone_0279186 crossref_primary_10_1007_s00535_024_02095_x |
Cites_doi | 10.1016/S0002-9440(10)62276-6 10.1016/j.ccr.2013.02.025 10.1155/2015/137981 10.1016/j.freeradbiomed.2012.03.024 10.1111/cas.12045 10.1002/1097-0142(19900415)65:8<1678::AID-CNCR2820650803>3.0.CO;2-N 10.1073/pnas.0905653106 10.1038/labinvest.2013.92 10.1186/s12943-016-0501-y 10.1016/j.nbd.2010.11.001 10.1002/stem.2473 10.1101/gr.133744.111 10.1038/nature03128 10.1093/bioinformatics/btu638 10.1093/bioinformatics/btp120 10.1371/journal.pone.0125255 10.1371/journal.pone.0057020 10.1007/s12015-007-9002-0 10.1038/nrclinonc.2012.61 10.1111/j.1349-7006.2009.01144.x 10.1158/0008-5472.CAN-10-3126 10.1158/1078-0432.CCR-07-0932 10.1111/cas.12860 10.1158/0008-5472.CAN-06-3126 10.1073/pnas.0530291100 10.1186/gb-2010-11-10-r106 10.1007/s00441-004-1018-z 10.1111/1759-7714.12291 10.1002/ar.a.10019 10.1016/S0021-9258(18)77174-3 10.1038/sj.cdd.4402283 10.1038/nmeth.1923 10.1158/0008-5472.CAN-13-1541 10.1007/s12094-010-0540-6 10.1007/s004320100289 10.1101/gad.262998.115 10.1038/sj.onc.1207097 |
ContentType | Journal Article |
Copyright | 2018 American Association for Cancer Research. Copyright American Association for Cancer Research Inc May 1, 2018 |
Copyright_xml | – notice: 2018 American Association for Cancer Research. – notice: Copyright American Association for Cancer Research Inc May 1, 2018 |
DBID | AAYXX CITATION NPM 7QO 7T5 7TO 7U9 8FD FR3 H94 P64 7X8 |
DOI | 10.1158/1078-0432.CCR-17-1932 |
DatabaseName | CrossRef PubMed Biotechnology Research Abstracts Immunology Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed Virology and AIDS Abstracts Biotechnology Research Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database AIDS and Cancer Research Abstracts Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic Virology and AIDS Abstracts PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1557-3265 |
EndPage | 2158 |
ExternalDocumentID | 29437792 10_1158_1078_0432_CCR_17_1932 |
Genre | Journal Article |
GroupedDBID | --- 18M 29B 2FS 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CITATION CS3 DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO OK1 P0W P2P QTD RCR RHI RNS SJN TR2 W2D W8F WOQ YKV NPM 7QO 7T5 7TO 7U9 8FD FR3 H94 P64 7X8 |
ID | FETCH-LOGICAL-c2482-52114f13485d1767bbc55f0b53c1044775cd7c9a9ef8ee1c7d29b7bfd9cac8803 |
ISSN | 1078-0432 1557-3265 |
IngestDate | Thu Jul 10 18:21:53 EDT 2025 Sat Jul 26 02:18:27 EDT 2025 Thu Apr 03 07:02:00 EDT 2025 Tue Jul 01 01:30:14 EDT 2025 Thu Apr 24 22:54:05 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
License | 2018 American Association for Cancer Research. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c2482-52114f13485d1767bbc55f0b53c1044775cd7c9a9ef8ee1c7d29b7bfd9cac8803 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 29437792 |
PQID | 2032617677 |
PQPubID | 2046235 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_2002208731 proquest_journals_2032617677 pubmed_primary_29437792 crossref_primary_10_1158_1078_0432_CCR_17_1932 crossref_citationtrail_10_1158_1078_0432_CCR_17_1932 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-05-01 |
PublicationDateYYYYMMDD | 2018-05-01 |
PublicationDate_xml | – month: 05 year: 2018 text: 2018-05-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Philadelphia |
PublicationTitle | Clinical cancer research |
PublicationTitleAlternate | Clin Cancer Res |
PublicationYear | 2018 |
Publisher | American Association for Cancer Research Inc |
Publisher_xml | – name: American Association for Cancer Research Inc |
References | Schuller (2022061102014617400_bib35) 2003; 270 Florek (2022061102014617400_bib10) 2005; 319 Uchida (2022061102014617400_bib12) 2016; 107 Zhao (2022061102014617400_bib18) 2013; 23 Ghosh (2022061102014617400_bib33) 2015; 2015 Sullivan (2022061102014617400_bib13) 2011; 41 Kubo (2022061102014617400_bib17) 2013; 104 Burger (2022061102014617400_bib36) 2003; 22 Kwon (2022061102014617400_bib37) 2015; 29 Williams (2022061102014617400_bib30) 2013; 93 Ries LAG (2022061102014617400_bib1) 2007 Wang (2022061102014617400_bib5) 2013; 8 Anders (2022061102014617400_bib22) 2015; 31 Anders (2022061102014617400_bib24) 2012; 22 Eramo (2022061102014617400_bib3) 2008; 15 Zeppernick (2022061102014617400_bib8) 2008; 14 Trapnell (2022061102014617400_bib21) 2009; 25 De Jongh (2022061102014617400_bib26) 1990; 265 Anderson (2022061102014617400_bib31) 2015; 10 Tentler (2022061102014617400_bib28) 2012; 9 Veeramani (2022061102014617400_bib32) 2012; 53 Langmead (2022061102014617400_bib20) 2012; 9 Fukuoka (2022061102014617400_bib2) 1990; 65 Clarke (2022061102014617400_bib4) 2006; 66 Sales (2022061102014617400_bib6) 2007; 3 Barnawi (2022061102014617400_bib27) 2016; 34 Meng (2022061102014617400_bib16) 2009; 100 Singh (2022061102014617400_bib11) 2004; 432 Al-Hajj (2022061102014617400_bib7) 2003; 100 Bertolini (2022061102014617400_bib15) 2009; 106 Fu (2022061102014617400_bib25) 2016; 7 Falcon (2022061102014617400_bib19) 2011; 71 Jull (2022061102014617400_bib34) 2001; 127 Anders (2022061102014617400_bib23) 2010; 11 Ciccarelli (2022061102014617400_bib38) 2016; 15 Bussolati (2022061102014617400_bib9) 2005; 166 Sarvi (2022061102014617400_bib14) 2014; 74 Jin (2022061102014617400_bib29) 2010; 12 |
References_xml | – volume-title: SEER Cancer Statistics Review, 1975–2004 year: 2007 ident: 2022061102014617400_bib1 – volume: 166 start-page: 545 year: 2005 ident: 2022061102014617400_bib9 article-title: Isolation of renal progenitor cells from adult human kidney publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)62276-6 – volume: 23 start-page: 541 year: 2013 ident: 2022061102014617400_bib18 article-title: 1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel alpha2delta1 subunit publication-title: Cancer Cell doi: 10.1016/j.ccr.2013.02.025 – volume: 2015 start-page: 137981 year: 2015 ident: 2022061102014617400_bib33 article-title: Characterization of Toll-like receptor-4 (TLR-4) in the spleen and thymus of Swiss albino mice and its modulation in experimental endotoxemia publication-title: J Immunol Res doi: 10.1155/2015/137981 – volume: 53 start-page: 95 year: 2012 ident: 2022061102014617400_bib32 article-title: Reactive oxygen species induced by p66Shc longevity protein mediate nongenomic androgen action via tyrosine phosphorylation signaling to enhance tumorigenicity of prostate cancer cells publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2012.03.024 – volume: 104 start-page: 78 year: 2013 ident: 2022061102014617400_bib17 article-title: Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy publication-title: Cancer Sci doi: 10.1111/cas.12045 – volume: 65 start-page: 1678 year: 1990 ident: 2022061102014617400_bib2 article-title: Combination chemotherapy with or without radiation therapy in small cell lung cancer. An analysis of a 5-year follow-up publication-title: Cancer doi: 10.1002/1097-0142(19900415)65:8<1678::AID-CNCR2820650803>3.0.CO;2-N – volume: 106 start-page: 16281 year: 2009 ident: 2022061102014617400_bib15 article-title: Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0905653106 – volume: 93 start-page: 970 year: 2013 ident: 2022061102014617400_bib30 article-title: Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century publication-title: Lab Invest doi: 10.1038/labinvest.2013.92 – volume: 15 start-page: 16 year: 2016 ident: 2022061102014617400_bib38 article-title: Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population publication-title: Mol Cancer doi: 10.1186/s12943-016-0501-y – volume: 41 start-page: 552 year: 2011 ident: 2022061102014617400_bib13 article-title: Effect of epithelial stem cell transplantation on noise-induced hearing loss in adult mice publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2010.11.001 – volume: 34 start-page: 2799 year: 2016 ident: 2022061102014617400_bib27 article-title: Fascin is critical for the maintenance of breast cancer stem cell pool predominantly via the activation of the notch self-renewal pathway publication-title: Stem Cells doi: 10.1002/stem.2473 – volume: 22 start-page: 2008 year: 2012 ident: 2022061102014617400_bib24 article-title: Detecting differential usage of exons from RNA-seq data publication-title: Genome Res doi: 10.1101/gr.133744.111 – volume: 432 start-page: 396 year: 2004 ident: 2022061102014617400_bib11 article-title: Identification of human brain tumour initiating cells publication-title: Nature doi: 10.1038/nature03128 – volume: 31 start-page: 166 year: 2015 ident: 2022061102014617400_bib22 article-title: HTSeq–a Python framework to work with high-throughput sequencing data publication-title: Bioinformatics doi: 10.1093/bioinformatics/btu638 – volume: 25 start-page: 1105 year: 2009 ident: 2022061102014617400_bib21 article-title: TopHat: discovering splice junctions with RNA-Seq publication-title: Bioinformatics doi: 10.1093/bioinformatics/btp120 – volume: 10 start-page: e0125255 year: 2015 ident: 2022061102014617400_bib31 article-title: Initiation and characterization of small cell lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspirates publication-title: PLoS One doi: 10.1371/journal.pone.0125255 – volume: 8 start-page: e57020 year: 2013 ident: 2022061102014617400_bib5 article-title: Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines publication-title: PLoS ONE doi: 10.1371/journal.pone.0057020 – volume: 3 start-page: 249 year: 2007 ident: 2022061102014617400_bib6 article-title: Stem cells and cancer: an overview publication-title: Stem Cell Rev doi: 10.1007/s12015-007-9002-0 – volume: 9 start-page: 338 year: 2012 ident: 2022061102014617400_bib28 article-title: Patient-derived tumour xenografts as models for oncology drug development publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2012.61 – volume: 100 start-page: 1040 year: 2009 ident: 2022061102014617400_bib16 article-title: Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2009.01144.x – volume: 71 start-page: 1573 year: 2011 ident: 2022061102014617400_bib19 article-title: Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-3126 – volume: 14 start-page: 123 year: 2008 ident: 2022061102014617400_bib8 article-title: Stem cell marker CD133 affects clinical outcome in glioma patients publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-0932 – volume: 107 start-page: 353 year: 2016 ident: 2022061102014617400_bib12 article-title: Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment publication-title: Cancer Sci doi: 10.1111/cas.12860 – volume: 66 start-page: 9339 year: 2006 ident: 2022061102014617400_bib4 article-title: Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-3126 – volume: 100 start-page: 3983 year: 2003 ident: 2022061102014617400_bib7 article-title: Prospective identification of tumorigenic breast cancer cells publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0530291100 – volume: 11 start-page: R106 year: 2010 ident: 2022061102014617400_bib23 article-title: Differential expression analysis for sequence count data publication-title: Genome Biol doi: 10.1186/gb-2010-11-10-r106 – volume: 319 start-page: 15 year: 2005 ident: 2022061102014617400_bib10 article-title: Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer publication-title: Cell Tissue Res doi: 10.1007/s00441-004-1018-z – volume: 7 start-page: 100 year: 2016 ident: 2022061102014617400_bib25 article-title: High-fidelity of non-small cell lung cancer xenograft models derived from bronchoscopy-guided biopsies publication-title: Thorac Cancer doi: 10.1111/1759-7714.12291 – volume: 270 start-page: 51 year: 2003 ident: 2022061102014617400_bib35 article-title: Receptor-mediated effects of nicotine and its nitrosated derivative NNK on pulmonary neuroendocrine cells publication-title: Anat Rec A Discov Mol Cell Evol Biol doi: 10.1002/ar.a.10019 – volume: 265 start-page: 14738 year: 1990 ident: 2022061102014617400_bib26 article-title: Subunits of purified calcium channels. Alpha 2 and delta are encoded by the same gene publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)77174-3 – volume: 15 start-page: 504 year: 2008 ident: 2022061102014617400_bib3 article-title: Identification and expansion of the tumorigenic lung cancer stem cell population publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4402283 – volume: 9 start-page: 357 year: 2012 ident: 2022061102014617400_bib20 article-title: Fast gapped-read alignment with Bowtie 2 publication-title: Nat Methods doi: 10.1038/nmeth.1923 – volume: 74 start-page: 1554 year: 2014 ident: 2022061102014617400_bib14 article-title: CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-13-1541 – volume: 12 start-page: 473 year: 2010 ident: 2022061102014617400_bib29 article-title: Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review publication-title: Clin Translat Oncol doi: 10.1007/s12094-010-0540-6 – volume: 127 start-page: 707 year: 2001 ident: 2022061102014617400_bib34 article-title: Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells publication-title: J Cancer Res Clin Oncol doi: 10.1007/s004320100289 – volume: 29 start-page: 1587 year: 2015 ident: 2022061102014617400_bib37 article-title: Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasis publication-title: Gene Dev doi: 10.1101/gad.262998.115 – volume: 22 start-page: 8093 year: 2003 ident: 2022061102014617400_bib36 article-title: Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells publication-title: Oncogene doi: 10.1038/sj.onc.1207097 |
SSID | ssj0014104 |
Score | 2.2539928 |
Snippet | Purpose: Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving... Chemoresistance in small-cell lung cancer (SCLC) is reportedly attributed to the existence of resistant cancer stem cells (CSC). Studies involving CSC-specific... |
SourceID | proquest pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 2148 |
SubjectTerms | Biotechnology Calcium Calcium channels (voltage-gated) Cancer Cell culture Cell self-renewal Chemoresistance Chemotherapy Drug resistance Electric potential Experimental design Gene expression Lung cancer Monoclonal antibodies Properties (attributes) Small cell lung carcinoma Stem cells Western blotting Xenografts Xenotransplantation |
Title | Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29437792 https://www.proquest.com/docview/2032617677 https://www.proquest.com/docview/2002208731 |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NjtMwELbKIiEuiH8KCzISe6pSGsepkyOELivUXSTUQjlFieOwldIU7TYHeBhOvAASz7HPxIzt_CxbxMIlrdwmtvJ9Gc9M5oeQZyMv5S7DOL-EK4dnaeqEocycxAvHMmcZWBS62ufR-GDO3yz8Ra_3vRO1VG3Sofy6Na_kf1CFMcAVs2T_AdnmojAA3wFfOALCcLwUxocK83Z1qeWBCaZrFMAI0TzBIK7VIEL_HCblwMD7dbEBEeK8ss1vN5idJZfVSucZlKoY7EWTvZcu0x_cRclSwWPv6BQTVE-xxIBN20L9_RQVUJQOSxAUq6QoHD3dtMJ4Ar2Irv4b1YmY0qzP1hpqfNIfK00r4OynL2u7qWp3v_VqH1fo4O54u7Wn94Natgq58ejiJeRxVXa9Gm7QxhDWgtgH4cdMH4mh2jJmpbfJwLYsDc-JYlPC8-Ie4QfaXYGlhbnHhlH0zoGtGjXZdlOsAwGO3sb78-k0nk0WsyvkKgNjBPtkvF40gUQYKKtjF-rV2TwxmOb51knOa0B_MGu0ejO7SW5Yu4S-MCS7RXqqvE2uHdrIizvkW4drtMM1us6pgZki1yiCTw3X6AWuUcs1arlGz36ws58u_Z1jtMsx2nKMLkvacowix-zkd8l8fzKLDhzb28ORjAfo_wBDPHc9HviZK8YiTaXv56PU9yTcTi6ELzMhwyRUeaCUK0XGwlSkeRbKRMKe490jO-W6VA8IlRxdPFL4Ict4wkehHAuRi0wGCdjr47xPeH2_Y2kL32P_lSLWBrAfxAhTjDDFAFPsihhh6pNhc9pnU_nlbyfs1mDGVkicxmzkYc8DWFGfPG1-BhGO7-WSUq0r_A-muwfCc_vkviFBMyMLOZYEZQ8vcfYjcr19lHbJzuakUo9BZd6kTzRjfwEa4L_G |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mechanistic+Exploration+of+Cancer+Stem+Cell+Marker+Voltage-Dependent+Calcium+Channel+%CE%B12%CE%B41+Subunit-mediated+Chemotherapy+Resistance+in+Small-Cell+Lung+Cancer&rft.jtitle=Clinical+cancer+research&rft.au=Yu%2C+Jiangyong&rft.au=Wang%2C+Shuhang&rft.au=Zhao%2C+Wei&rft.au=Duan%2C+Jianchun&rft.date=2018-05-01&rft.issn=1557-3265&rft.eissn=1557-3265&rft.volume=24&rft.issue=9&rft.spage=2148&rft_id=info:doi/10.1158%2F1078-0432.CCR-17-1932&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |